relapse-free survival. 4 It may therefore mean that the degree of remission achieved after DLI and not the kind of conditioning regimen preceding allografting would determine the durability of response. We have reported two cases of DLI-induced molecular remissions in myeloma patients.
Susceptibility of malignant plasma cells to HA-1
H specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect Leukemia (2004) 18, 1543-1545. doi:10.1038/sj.leu.2403445
TO THE EDITOR
Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions (DLIs) can induce durable remissions in patients with multiple myeloma (MM). This beneficial graftversus-myeloma (GvM) effect is largely mediated by immunocompetent, allo-reactive donor T cells present in the stem cell grafts, as suggested by the close correlation between the occurrence of graft-versus-host disease (GvHD) and clinical response to DLI. 1, 2 In an HLA-identical SCT, allo-reactive donor T cells recognize Minor Histocompatibility antigens (mHags) presented by HLA molecules of the recipient. mHags are immunogenic peptides derived from polymorphic cellular proteins. Of the identified mHags, HA-1 appears to be one of the most interesting minors from a clinical point of view. It is exclusively expressed in hematopoietic cells, induces strong cytotoxic T lymphocyte (CTL) responses and has been associated with graft-versusleukemia (GvL). 3, 4 Recently, HA-1 gene transcription was demonstrated in CD138 þ cells isolated from a plasma cell leukemia patient. Furthermore, treatment of an MM patient with DLI from an HLA-identical, HA-1 mismatched donor resulted in a durable remission that correlated with the emergence of circulating HA-1 CTLs. 3 These data suggest that malignant cells may be targets for HA-1 CTLs. However, until now, no functional data have been reported demonstrating HA-1-specific lysis of malignant plasma cells.
We addressed the susceptibility of MM cells for HA-1-specific lysis using eight MM cell lines and primary MM cells, freshly isolated from six MM patients.
First HA-1 gene expression of MM cells was examined by genomic typing (Figure 1a ) as described previously. Primary MM cells were isolated as described previously 6 and were 70-95% pure myeloma cells, as determined by coexpression of CD38/CD138 and the expression of kappa or lambda in a FACS analysis. The susceptibility of primary MM cells to HA-1 H -mediated cytotoxic activity was tested in a standard 51 Cr cytotoxicity assay using an HA-1 H -specific clone that was previously isolated from a chronic myeloid leukemia patient. 4 HA-1 H CTL cytotoxicity is directed solely against HA-1 H as it did not lyse HLA-A2 À or HA-1 HÀ target cells and showed no NK-like activity (data not shown).
Prior to cytotoxicity assays, the HLA-A2 surface expression of MM cells was analyzed by FACS (data not shown) using a polyclonal anti-HLA-A2 serum (a kind gift from Dr H Otten, UMCU, Utrecht, The Netherlands). Functional HLA-A2 expression was tested using an allo-HLA-A2-specific CTL (allo-A2 CTLs H CTLs, suggesting that UM6 was either resistant to lysis by HA-1 H CTLs or was defective in the presentation of the HA-1 H peptide. To discriminate between these possibilities, UM6 was tested after pulsing with HA-1 H peptide and after IFN-g treatment (Figure 2b ). PHA blasts generated from the original patient of UM6 were tested as target cells to determine whether normal hematopoietic cells also showed such a defect. After pulsing with HA-1 H peptide, the MM cell line UM6 was effectively lysed by HA-1 H CTLs. These results suggested that UM6 was susceptible to lysis, but did not express HLA-A2 properly. IFN-g treatment induced low, but significant, levels of lysis of the unpulsed UM6, but had a significant positive effect on the lysis of peptide-pulsed UM6 (Figure 2b) . The defective HA-1 H presentation was specific for the cell line UM6, since the PHA blasts derived from the same patient were efficiently lysed by HA-1 H CTLs (Figure 2b) . A similar phenomenon has been described for tumorassociated antigens gp100, MAGE and HB-1 in which specific lysis does not occur if gene transcription is too low. [7] [8] [9] An escape mechanism from HA-1 H -specific CTL lysis was also recently observed in solid tumor cell lines. 10 Quantification of HA-1 transcription by real-time PCR may yield additional insight into this issue. Alternatively, the defect in the UM6 MM cell line can be at the antigen-processing level as IFN-g can upregulate proteasomal antigen processing by inducing a switch from constitutive-to immunoproteasomes. 11 It remains, however, to be proven whether this represents an immune escape mechanism by MM cells or a cell-culture artifact. Either way, UM6 may be an interesting cell line to examine the regulation and presentation of HA-1 
